Jasper Therapeutics Stock Analysis
JSPR Stock | USD 23.24 0.61 2.70% |
Jasper Therapeutics is overvalued with Real Value of 18.05 and Target Price of 7.0. The main objective of Jasper Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Jasper Therapeutics is worth, separate from its market price. There are two main types of Jasper Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Jasper Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Jasper Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Jasper Stock trading window is adjusted to America/New York timezone.
Jasper |
Jasper Stock Analysis Notes
About 95.0% of the company shares are owned by institutional investors. The book value of Jasper Therapeutics was currently reported as 5.58. The company recorded a loss per share of 4.75. Jasper Therapeutics had not issued any dividends in recent years. The entity had 1:10 split on the 4th of January 2024. Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Jasper Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 35 people. To learn more about Jasper Therapeutics call Ronald Martell at 650 549 1400 or check out https://www.jaspertherapeutics.com/.Jasper Therapeutics Investment Alerts
Jasper Therapeutics had very high historical volatility over the last 90 days | |
Net Loss for the year was (64.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Jasper Therapeutics currently holds about 60.81 M in cash with (52.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.6. | |
Over 95.0% of the company shares are owned by institutional investors | |
Latest headline from news.google.com: Jasper Therapeutics Briquilimabs Potential In Chronic Urticaria And Asthma - Seeking Alpha |
Jasper Therapeutics Upcoming and Recent Events
13th of March 2024 Upcoming Quarterly Report | View | |
10th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
13th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Jasper Largest EPS Surprises
Earnings surprises can significantly impact Jasper Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-08-09 | 2024-06-30 | -1.09 | -0.97 | 0.12 | 11 | ||
2024-11-07 | 2024-09-30 | -1.07 | -1.24 | -0.17 | 15 | ||
2024-05-14 | 2024-03-31 | -1.23 | -1.03 | 0.2 | 16 |
Jasper Therapeutics Environmental, Social, and Governance (ESG) Scores
Jasper Therapeutics' ESG score is a quantitative measure that evaluates Jasper Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Jasper Therapeutics' operations that may have significant financial implications and affect Jasper Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Jasper Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Braidwell Lp | 2024-09-30 | 483.3 K | Woodline Partners Lp | 2024-06-30 | 413.9 K | Rock Springs Capital Management Lp | 2024-06-30 | 404.3 K | Great Point Partners Llc | 2024-06-30 | 402 K | Ally Bridge Group (ny) Llc | 2024-09-30 | 399.5 K | Opaleye Management Inc | 2024-09-30 | 353.5 K | Boxer Capital Llc | 2024-09-30 | 350 K | Integral Health Asset Management, Llc | 2024-09-30 | 350 K | Bank Of America Corp | 2024-06-30 | 325.3 K | Velan Capital Investment Management Lp | 2024-06-30 | 1.5 M | Soleus Capital Management, L.p. | 2024-06-30 | 1.3 M |
Jasper Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 348.63 M.Jasper Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.68) | (0.71) | |
Return On Capital Employed | (0.83) | (0.88) | |
Return On Assets | (0.68) | (0.71) | |
Return On Equity | (0.82) | (0.78) |
Management Efficiency
Jasper Therapeutics has return on total asset (ROA) of (0.4092) % which means that it has lost $0.4092 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7146) %, meaning that it created substantial loss on money invested by shareholders. Jasper Therapeutics' management efficiency ratios could be used to measure how well Jasper Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/29/2024, Return On Tangible Assets is likely to drop to -0.71. In addition to that, Return On Capital Employed is likely to drop to -0.88. At this time, Jasper Therapeutics' Net Tangible Assets are relatively stable compared to the past year. As of 11/29/2024, Other Current Assets is likely to grow to about 1.9 M, while Total Assets are likely to drop slightly above 63.2 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 7.51 | 7.89 | |
Tangible Book Value Per Share | 7.51 | 7.89 | |
Enterprise Value Over EBITDA | 0.03 | 0.03 | |
Price Book Value Ratio | 1.05 | 1.10 | |
Enterprise Value Multiple | 0.03 | 0.03 | |
Price Fair Value | 1.05 | 1.10 | |
Enterprise Value | -19.5 M | -18.5 M |
Effective leadership at Jasper Therapeutics drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta 2.199 | Return On Assets (0.41) | Return On Equity (0.71) |
Technical Drivers
As of the 29th of November, Jasper Therapeutics retains the Market Risk Adjusted Performance of 0.12, downside deviation of 5.09, and Risk Adjusted Performance of 0.0597. Jasper Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Jasper Therapeutics variance and potential upside to decide if Jasper Therapeutics is priced fairly, providing market reflects its last-minute price of 23.24 per share. Given that Jasper Therapeutics has jensen alpha of (0.02), we strongly advise you to confirm Jasper Therapeutics's regular market performance to make sure the company can sustain itself at a future point.Jasper Therapeutics Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Jasper Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Jasper Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Jasper Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Jasper Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Jasper Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Jasper Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Jasper Therapeutics Outstanding Bonds
Jasper Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Jasper Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Jasper bonds can be classified according to their maturity, which is the date when Jasper Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Jasper Therapeutics Predictive Daily Indicators
Jasper Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Jasper Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Jasper Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
13A | 4th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 22nd of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 15th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 12th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 13th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 20th of June 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Jasper Therapeutics Forecast Models
Jasper Therapeutics' time-series forecasting models are one of many Jasper Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Jasper Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Jasper Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Jasper Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Jasper shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Jasper Therapeutics. By using and applying Jasper Stock analysis, traders can create a robust methodology for identifying Jasper entry and exit points for their positions.
Last Reported | Projected for Next Year |
Current Jasper Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Jasper analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Jasper analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
7.0 | Strong Buy | 10 | Odds |
Most Jasper analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Jasper stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Jasper Therapeutics, talking to its executives and customers, or listening to Jasper conference calls.
Jasper Stock Analysis Indicators
Jasper Therapeutics stock analysis indicators help investors evaluate how Jasper Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Jasper Therapeutics shares will generate the highest return on investment. By understating and applying Jasper Therapeutics stock analysis, traders can identify Jasper Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 38.7 M | |
Common Stock Shares Outstanding | 10.4 M | |
Total Stockholder Equity | 78.4 M | |
Property Plant And Equipment Net | 4.2 M | |
Cash And Short Term Investments | 86.9 M | |
Cash | 86.9 M | |
Accounts Payable | 4.1 M | |
Net Debt | -84.1 M | |
50 Day M A | 20.2695 | |
Total Current Liabilities | 12.4 M | |
Other Operating Expenses | 68.9 M | |
Non Current Assets Total | 6 M | |
Non Currrent Assets Other | 1.8 M | |
Stock Based Compensation | 5.2 M |
Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.